Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
1. EBS secured a $56 million contract modification for ACAM2000® vaccine. 2. Total projected sales for ACAM2000® exceed $120 million this year. 3. Deliveries of the vaccine to the U.S. government start this month. 4. ACAM2000® is approved for smallpox and mpox immunization. 5. Emergent emphasizes commitment to public health collaborations with the government.